All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.

The MDS Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy


Now you can personalise
your MDS Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more

The MDS Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MDS Hub cannot guarantee the accuracy of translated content. The MDS Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.
As of January 1st, 2024, the MDS Hub will no longer be updated. Please continue to browse our archive for valuable content. For the latest updates in MDS, visit our sister site

"How I treat” based on the new/updated classification systems

Dec 14, 2023
Learning objective: After reading this article, learners will be able to cite a new clinical development in MDS.

Bookmark this article

During the MDS Hub Steering Committee meeting, held on October 26, 2023, Pierre Fenaux chaired a “How I treat” discussion based on the new/updated classification systems in myelodysplastic syndromes (MDS), with contributions from Theo de Witte and Yasushi Miyazaki.

“How I treat” based on the new/updated classification systems

Fenaux highlights the differences between the 5th edition of the World Health Organization Classification of Hematolymphoid Tumors and the International Consensus Classification of Myeloid Neoplasms and Acute Leukemia, outlining the consequences of these differences in the management of MDS. He also discusses the Molecular International Prognostic Scoring System and the impact of a patient's mutational profile on treatment decision-making. Fenaux continues by describing the updates in the International Working Group 2023 response criteria for higher-risk (MDS). To conclude, the committee discusses factors that influence transplant decision-making and the use of azacitidine and venetoclax as a bridge to transplant.


Subscribe to get the best content related to MDS delivered to your inbox